Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics
Vertex Pharmaceuticals Incorporated (VRTX)
Today's Latest Price: $210.08 USD
Updated Oct 22 4:00pm
Add VRTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VRTX Stock Summary
- VRTX has a market capitalization of $55,057,585,061 -- more than approximately 96.38% of US stocks.
- Over the past twelve months, VRTX has reported earnings growth of 158.49%, putting it ahead of 92% of US stocks in our set.
- The volatility of Vertex Pharmaceuticals Inc's share price is greater than that of only 6.98% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to VRTX, based on their financial statements, market capitalization, and price volatility, are MU, AMAT, LRCX, EA, and XLNX.
- Visit VRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.vrtx.com.
VRTX Stock Price Chart Interactive Chart >
VRTX Price/Volume Stats
| Current price | $210.08 | 52-week high | $306.08 |
| Prev. close | $211.38 | 52-week low | $186.41 |
| Day low | $208.23 | Volume | 2,380,500 |
| Day high | $214.74 | Avg. volume | 1,822,929 |
| 50-day MA | $262.14 | Dividend yield | N/A |
| 200-day MA | $259.12 | Market Cap | 54.72B |
Vertex Pharmaceuticals Incorporated (VRTX) Company Bio
Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.
VRTX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $210.08 | $43946 | 20384% |
We started the process of determining a valid price forecast for Vertex Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 20484.17% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:
- The compound growth rate in the free cash flow of Vertex Pharmaceuticals Inc over the past 3.75 years is 2.59%; that's higher than 93.01% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.06% of the free cash flow producing stocks we're observing.
- VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.9% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 19982% |
| 1% | 20183% |
| 2% | 20384% |
| 3% | 20585% |
| 4% | 20785% |
| 5% | 20986% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as VRTX, try KMDA, ASNB, GEN, AMEH, and AMRX.
Loading social stream, please wait...